Special Issue

Management of Recurrent Endometrial Cancer

Message from the Guest Editors

The incidence of endometrial cancer is rising globally at an alarming rate. Worldwide, mortality from endometrial cancer has increased significantly over the last two decades. With rising obesity, endometrial cancer is a health problem for women globally. There is an increasing trend towards seeing younger women present with endometrial cancer for what was once described as a cancer of elderly post-menopausal women. Approximately 15-20% of all patients diagnosed with endometrial cancer will recur after primary treatment, and most of this recurrence unfortunately happens in the first 2-3 years after initial diagnosis. Treatment for recurrent endometrial cancer varies between local, systemic, or surgical treatment. Current molecular stratification has shown an impact on prognosis for endometrial cancer. Appropriate staging for endometrial cancer at primary surgery dictates the need for appropriate adjuvant treatment. There continues to be considerable variation in the approach to treating advanced endometrial cancer. Further research is required to fully understand the role of molecular stratification in streamlining treatment in the recurrent setting.

Guest Editors

Prof. Dr. Jayanta Chatterjee

Dr. Alexandra Stewart

Dr. Hersha Patel

Prof. Dr. Emmanouil Karteris

Deadline for manuscript submissions

closed (30 May 2025)



Cancers

an Open Access Journal by MDPI

Impact Factor 4.4
CiteScore 8.8
Indexed in PubMed



mdpi.com/si/213242

Cancers
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
cancers@mdpi.com

mdpi.com/journal/cancers





Cancers

an Open Access Journal by MDPI

Impact Factor 4.4 CiteScore 8.8 Indexed in PubMed



About the Journal

Message from the Editor-in-Chief

Cancers is an international online journal addressing both clinical and basic science issues related to cancer research. The journal is publishing in Open Access format, which will certainly evolve to ensure that the journal takes full advantage of the rapidly changing world of information and knowledge dissemination. It publishes high-quality clinical, translational, and basic science research on cancer prevention, initiation, progression, and treatment, as well as other related topics, particularly to capture the most seminal studies in the rapidly growing area of immunology, immunotherapy, and tumor microenvironment.

Editor-in-Chief

Prof. Dr. Samuel C. Mok.

Department of Gynecologic Oncology and Reproductive Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA

Author Benefits

Open Access:

free for readers, with article processing charges (APC) paid by authors or their institutions.

High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPlus / SciFinder, and other databases.

Journal Rank:

JCR - Q2 (Oncology) / CiteScore - Q1 (Oncology)

